Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Chinese Patent Office
McKesson
Medtronic
Merck
Chubb
Federal Trade Commission
Julphar
Dow

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HYDROMORPHONE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Hydromorphone Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00003115 Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy Completed Roswell Park Cancer Institute Phase 3 RATIONALE: Giving hydromorphone in different ways may relieve the pain associated with cancer surgery. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of epidural hydromorphone with hydromorphone infusion in patients with prostate cancer undergoing radical prostatectomy.
NCT00125801 The Pain Pen for Breakthrough Cancer Pain Terminated Erasmus Medical Center Phase 3 The purpose of this study is to see whether injection of hydromorphone through a subcutaneous injection device is more effective in treating breakthrough cancer pain than oral morphine.
NCT00134875 Assessing Abuse Potential of Parenteral Buprenorphine/Naloxone in Non-Dependent Opioid Abusers Terminated National Institute of Allergy and Infectious Diseases (NIAID) N/A Buprenorphine, a treatment for opioid dependence, can be mixed with another drug, naloxone, to limit abuse potential. Parenteral administration (intravenous or intramuscular injection) of buprenorphine/naloxone causes withdrawal symptoms in opioid dependent individuals. However, naloxone does not cause withdrawal symptoms in non-dependent opioid abusers. This study will investigate whether naloxone decreases the opioid agonist effect from injected buprenorphine, hence decreasing the abuse potential of buprenorphine/naloxone, in non-dependent opioid abusers.
NCT00134888 Blockade Efficacy of Buprenorphine/Naloxone For Opioid Dependence Completed National Institute on Drug Abuse (NIDA) N/A Buprenorphine, a treatment for opioid dependence, can be mixed with naloxone, to limit abuse potential. The purpose of this study is to examine the effectiveness of buprenorphine/naloxone that is given at less than daily intervals, in order to prevent withdrawal symptoms associated with stopping opioid abuse.
NCT00134914 Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence Completed National Institute on Drug Abuse (NIDA) N/A Buprenorphine is a treatment for opioid dependence. Naloxone is given in addition to buprenorphine in order to limit the abuse potential that is commonly associated with buprenorphine. The purpose of this study is to examine the effects of buprenorphine/naloxone when given through different routes and at different doses.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Hydromorphone Hydrochloride

Condition Name

Condition Name for Hydromorphone Hydrochloride
Intervention Trials
Pain 56
Postoperative Pain 17
Acute Pain 16
Pain, Postoperative 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Hydromorphone Hydrochloride
Intervention Trials
Pain, Postoperative 40
Acute Pain 20
Chronic Pain 10
Opioid-Related Disorders 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Hydromorphone Hydrochloride

Trials by Country

Trials by Country for Hydromorphone Hydrochloride
Location Trials
United States 179
Canada 18
Germany 6
China 4
Austria 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Hydromorphone Hydrochloride
Location Trials
New York 31
Illinois 16
Texas 13
Ohio 10
Massachusetts 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Hydromorphone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Hydromorphone Hydrochloride
Clinical Trial Phase Trials
Phase 4 83
Phase 3 43
Phase 2/Phase 3 1
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Hydromorphone Hydrochloride
Clinical Trial Phase Trials
Completed 92
Recruiting 46
Not yet recruiting 28
[disabled in preview] 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Hydromorphone Hydrochloride

Sponsor Name

Sponsor Name for Hydromorphone Hydrochloride
Sponsor Trials
Montefiore Medical Center 16
Alza Corporation, DE, USA 14
National Institute on Drug Abuse (NIDA) 12
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Hydromorphone Hydrochloride
Sponsor Trials
Other 183
Industry 69
NIH 15
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Cerilliant
McKinsey
Cantor Fitzgerald
Queensland Health
Teva
Citi
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.